Generic Xeloda Now Available

Last week, the Food and Drug Administration (FDA) approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat metastatic colorectal cancer. Kathleen Uhl, M.D., acting director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research, says “Generic drugs are important options that allow greater access…  Read More

Avastin with XELIRI or FOLFIRI: Is There Any Difference?

When Avastin is added to the combination of Xeloda and irinotecan as an initial treatment for advanced colorectal cancer, the treatment is equally effective as Avastin with FOLFIRI. But side effects are more difficult. After a randomized clinical trial comparing Avastin with XELIRI (Xeloda, irinotecan) to Avastin with FOLFIRI (5-FU, leucovorin, irinotecan), researchers concluded that excessive…  Read More

Hand-Foot Syndrome Signals Xeloda Effectiveness

Developing tender swelling or rash on their hands and feet may actually be good news for patients being treated with Xeloda® (capecitabine). During a recent clinical trial, colorectal cancer patients with hand-foot syndrome lived longer, and it took longer for their cancer to get worse. Researchers comparing two Xeloda-based chemotherapies for people with advanced colorectal cancer,…  Read More

Avastin Helps Patients Maintain Chemotherapy Effectiveness

It doesn’t hurt to stop XELOX chemotherapy combined with Avastin after six treatments and continue with Avastin alone until colorectal cancer gets worse, according to a study reported at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago. Many patients have to stop oxaliplatin chemotherapy with before getting its maximum effectiveness because…  Read More

Older patients benefit from XELOX after surgery

Update from 2010 GI Cancers Symposium Colon cancer patients over 70 actually had a greater reduction in disease-free survival than did younger ones with a new regimen of Xeloda® and oxaliplatin compared to older IV 5-FU treatments according to a new analysis reported at the GI Cancers Symposium in Orlando. With the bolus IV 5-FU and…  Read More

XELOX Beats 5-FU with Fewer Recurrences

A combination of Xeloda and Eloxatin (XELOX) was better than standard 5-FU and leucovorin chemotherapy in reducing recurrences of stage III colon cancer after surgery.  Significantly more patients receiving XELOX were alive without cancer three years after treatment began. Roche announced results of a Phase III clinical trial that compared XELOX chemotherapy to bolus 5-FU and…  Read More